Mirati Therapeutics | MRTX - أصول متداولة



أصول متداولة تغيير تاريخ
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Astellas Pharma JPY 1.42T 19.35B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bayer EUR 35.3B 2.39B 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eisai JPY 761.64B 79.24B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Exelixis USD 1.21B 234.65M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Takeda JPY 3.09T 25.94B 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03